Design, Synthesis, and Monoamine Oxidase Inhibitory Activity of (+)-Cinchonaminone and Its Simplified Derivatives.


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
09 Sep 2021
Historique:
received: 01 06 2021
accepted: 13 08 2021
entrez: 17 9 2021
pubmed: 18 9 2021
medline: 18 9 2021
Statut: epublish

Résumé

The absolute structure of an indole alkaloid (+)-cinchonaminone by total synthesis of both (+)-cinchonaminone and its enantiomer was determined. The main focus of the study was the enantioselective synthesis of both enantiomers of a chiral

Identifiants

pubmed: 34531955
doi: 10.1021/acsmedchemlett.1c00310
pmc: PMC8436416
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1464-1469

Informations de copyright

© 2021 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Aug 1;69:81-9
pubmed: 26891670
J Neural Transm (Vienna). 2018 Nov;125(11):1519-1551
pubmed: 29637260
Front Pharmacol. 2016 Oct 18;7:340
pubmed: 27803666
Medchemcomm. 2018 Nov 24;10(1):10-25
pubmed: 30774851
J Med Chem. 2007 Nov 15;50(23):5848-52
pubmed: 17915852
J Org Chem. 2017 Dec 15;82(24):13342-13347
pubmed: 29131620
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5739-44
pubmed: 18391214
ACS Appl Mater Interfaces. 2018 Nov 21;10(46):39557-39569
pubmed: 30352150
J Org Chem. 2002 Aug 23;67(17):6256-9
pubmed: 12182675
Chem Pharm Bull (Tokyo). 1989 Feb;37(2):363-6
pubmed: 2743481
Chem Commun (Camb). 2014 Dec 28;50(100):15901-4
pubmed: 25380514
J Med Chem. 1994 Aug 19;37(17):2721-34
pubmed: 8064800

Auteurs

Yuta Sato (Y)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan.

Naoko Oyobe (N)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan.

Takao Ogawa (T)

Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0808, Japan.

Sayo Suzuki (S)

Graduate School of Pharmaceutical Sciences, Keio University, Shibakoen 1-5-30, Minato-ku, Tokyo 105-8512, Japan.

Hiroshi Aoyama (H)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan.

Tomonori Nakamura (T)

Graduate School of Pharmaceutical Sciences, Keio University, Shibakoen 1-5-30, Minato-ku, Tokyo 105-8512, Japan.

Hiromichi Fujioka (H)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan.

Satoshi Shuto (S)

Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0808, Japan.

Mitsuhiro Arisawa (M)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan.
Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0808, Japan.

Classifications MeSH